Craig D. Shimasaki
Fondateur chez Moleculera Labs, Inc.
Profil
Craig D.
Shimasaki was the founder of InterGenetics, Inc. (founded in 1999) where he held the title of President & Chief Executive Officer, and Moleculera Labs, Inc. (founded in 2011) where he previously held the title of President, Chief Executive Officer & Director.
He is currently a Director at i2E, Inc. where he is employed.
He previously worked as Vice President-Research at Zymetx, Inc. Dr. Shimasaki received his undergraduate degree from the University of California, Davis, his doctorate from The University of Tulsa, and his MBA from Kellogg School of Management.
Postes actifs de Craig D. Shimasaki
| Sociétés | Poste | Début |
|---|---|---|
Moleculera Labs, Inc.
 Moleculera Labs, Inc. Medical/Nursing ServicesHealth Services Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK. | Fondateur | 01/01/2011 |
| i2E, Inc. | Directeur/Membre du Conseil | - |
Anciens postes connus de Craig D. Shimasaki
| Sociétés | Poste | Fin |
|---|---|---|
Zymetx, Inc.
 Zymetx, Inc. Medical SpecialtiesHealth Technology ZymeTx, Inc is a biotechnology company, which is engaged in the discovery, development and commercialization of products used to diagnose and treat viruses. The company's ViraZme technology focuses on the development of molecules that interacts with an enzyme of specific origin, such as viral, mammalian or bacterial origin. It was founded in 1994 and is headquartered in Oklahoma City, OK. | Corporate Officer/Principal | - |
InterGenetics, Inc.
 InterGenetics, Inc. Medical/Nursing ServicesHealth Services InterGenetics, Inc. researches and develops therapeutics for the prevention, diagnostics, and treatment of cancer. Its core research has future application in predicting heart disease, diabetes and in drug therapies and preventative medicine. The company was founded by Eldon R. Jupe, David A. Ralph and Craig D. Shimasaki in 1999 and is headquartered in Oklahoma City, OK. | Directeur Général | - |
Formation de Craig D. Shimasaki
| University of California, Davis | Undergraduate Degree |
| The University of Tulsa | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
InterGenetics, Inc.
InterGenetics, Inc. Medical/Nursing ServicesHealth Services InterGenetics, Inc. researches and develops therapeutics for the prevention, diagnostics, and treatment of cancer. Its core research has future application in predicting heart disease, diabetes and in drug therapies and preventative medicine. The company was founded by Eldon R. Jupe, David A. Ralph and Craig D. Shimasaki in 1999 and is headquartered in Oklahoma City, OK. | Health Services |
Zymetx, Inc.
Zymetx, Inc. Medical SpecialtiesHealth Technology ZymeTx, Inc is a biotechnology company, which is engaged in the discovery, development and commercialization of products used to diagnose and treat viruses. The company's ViraZme technology focuses on the development of molecules that interacts with an enzyme of specific origin, such as viral, mammalian or bacterial origin. It was founded in 1994 and is headquartered in Oklahoma City, OK. | Health Technology |
Moleculera Labs, Inc.
Moleculera Labs, Inc. Medical/Nursing ServicesHealth Services Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK. | Health Services |
| i2E, Inc. |
